Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients

SIMPLE SUMMARY: Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of specific hematological diseases, but is unsuccessful in around 60% of patients. The objective of the Bio-CAR-T BS study is to improve our understanding of the lymphocyte harvest to maximize the quality...

Descripción completa

Detalles Bibliográficos
Autores principales: Farina, Mirko, Chiarini, Marco, Almici, Camillo, Accorsi Buttini, Eugenia, Zuccalà, Francesco, Piva, Simone, Volonghi, Irene, Poli, Loris, Bernardi, Simona, Colnaghi, Federica, Re, Federica, Leoni, Alessandro, Polverelli, Nicola, Turra, Alessandro, Morello, Enrico, Galvagni, Anna, Moratto, Daniele, Brugnoni, Duilio, Cattaneo, Chiara, Ferrari, Emilio, Bianchetti, Andrea, Malagola, Michele, Re, Alessandro, Russo, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655620/
https://www.ncbi.nlm.nih.gov/pubmed/36358694
http://dx.doi.org/10.3390/cancers14215276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655620/
https://www.ncbi.nlm.nih.gov/pubmed/36358694
http://dx.doi.org/10.3390/cancers14215276

Ejemplares similares